CN100447142C - 咪唑并[1,5a]吡啶衍生物及治疗醛固酮所介导疾病的方法 - Google Patents

咪唑并[1,5a]吡啶衍生物及治疗醛固酮所介导疾病的方法 Download PDF

Info

Publication number
CN100447142C
CN100447142C CNB2003801035050A CN200380103505A CN100447142C CN 100447142 C CN100447142 C CN 100447142C CN B2003801035050 A CNB2003801035050 A CN B2003801035050A CN 200380103505 A CN200380103505 A CN 200380103505A CN 100447142 C CN100447142 C CN 100447142C
Authority
CN
China
Prior art keywords
group
imidazo
formula
carbon atoms
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB2003801035050A
Other languages
English (en)
Chinese (zh)
Other versions
CN1711262A (zh
Inventor
F·菲罗兹尼亚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1711262A publication Critical patent/CN1711262A/zh
Application granted granted Critical
Publication of CN100447142C publication Critical patent/CN100447142C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNB2003801035050A 2002-11-18 2003-11-17 咪唑并[1,5a]吡啶衍生物及治疗醛固酮所介导疾病的方法 Expired - Fee Related CN100447142C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42732502P 2002-11-18 2002-11-18
US60/427,325 2002-11-18

Publications (2)

Publication Number Publication Date
CN1711262A CN1711262A (zh) 2005-12-21
CN100447142C true CN100447142C (zh) 2008-12-31

Family

ID=32326521

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2003801035050A Expired - Fee Related CN100447142C (zh) 2002-11-18 2003-11-17 咪唑并[1,5a]吡啶衍生物及治疗醛固酮所介导疾病的方法

Country Status (12)

Country Link
US (2) US7223866B2 (enExample)
EP (1) EP1565463B1 (enExample)
JP (1) JP2006508970A (enExample)
CN (1) CN100447142C (enExample)
AT (1) ATE398124T1 (enExample)
AU (1) AU2003292039A1 (enExample)
BR (1) BR0316306A (enExample)
CA (1) CA2505752A1 (enExample)
DE (1) DE60321593D1 (enExample)
ES (1) ES2305520T3 (enExample)
PT (1) PT1565463E (enExample)
WO (1) WO2004046145A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4422034B2 (ja) * 2002-12-06 2010-02-24 バイエル・ヘルスケア・アクチェンゲゼルシャフト テトラヒドロ−ナフタレン誘導体
EP1572632B1 (en) * 2002-12-09 2008-08-13 Xention Limited Tetrahydro-naphthalene derivatives as vanilloid receptor antagonists
EP1853261B1 (de) * 2005-03-03 2017-01-11 Universität des Saarlandes Selektive hemmstoffe humaner corticoidsynthasen
TW200716105A (en) * 2005-05-31 2007-05-01 Speedel Experimenta Ag Imidazole compounds
TW200716634A (en) * 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
TW200716636A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
EP1842543A1 (en) 2006-04-05 2007-10-10 Speedel Pharma AG Pharmaceutical composition coprising an aldosterone synthase inhibitor and a mineralcorticoid receptor antagonist
US7803810B2 (en) * 2007-03-09 2010-09-28 Probiodrug Ag Inhibitors
ES2448839T3 (es) 2007-11-01 2014-03-17 Bristol-Myers Squibb Company Compuestos no esteroideos útiles como moderadores de la actividad del receptor de glucocorticoides AP-1 y/o NF-kappa b y uso de los mismos
EP2095819A1 (en) 2008-02-28 2009-09-02 Maastricht University N-benzyl imidazole derivatives and their use as aldosterone synthase inhibitors
JP5420761B2 (ja) 2009-05-28 2014-02-19 ノバルティス アーゲー ネプリリシン阻害剤としての置換アミノプロピオン酸誘導体
KR20120041702A (ko) 2009-05-28 2012-05-02 노파르티스 아게 네프릴리신 억제제로서의 치환된 아미노부티르산 유도체
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
WO2011064376A1 (en) * 2009-11-30 2011-06-03 Novartis Ag Imidazole derivatives as aldosterone synthase inhibitors
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
TWI627167B (zh) 2011-07-08 2018-06-21 諾華公司 用於高三酸甘油酯個體治療動脈粥狀硬化之方法
EP2757882B1 (en) * 2011-09-22 2020-11-04 Merck Sharp & Dohme Corp. Imidazopyridyl compounds as aldosterone synthase inhibitors
WO2013043521A1 (en) 2011-09-22 2013-03-28 Merck Sharp & Dohme Corp. Pyrazolopyridyl compounds as aldosterone synthase inhibitors
EP2757883B1 (en) 2011-09-22 2021-01-13 Merck Sharp & Dohme Corp. Triazolopyridyl compounds as aldosterone synthase inhibitors
JO3137B1 (ar) 2012-01-17 2017-09-20 Novartis Ag أملاح وأشكال جديدة لمثبط إنزيم سينثاز أو أروماتاز ثنائي هيدروبيرولو [2،1-c] إيميدازوليل ألدوستيرون
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
WO2014126979A1 (en) 2013-02-14 2014-08-21 Novartis Ag Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors
CA2918074A1 (en) 2013-07-25 2015-01-29 Novartis Ag Cyclic polypeptides for the treatment of heart failure
CA2918077A1 (en) 2013-07-25 2015-01-29 Novartis Ag Bioconjugates of synthetic apelin polypeptides
AU2016209968B2 (en) 2015-01-23 2018-11-29 Novartis Ag Synthetic apelin fatty acid conjugates with improved half-life
GB201511790D0 (en) * 2015-07-06 2015-08-19 Iomet Pharma Ltd Pharmaceutical compound
JOP20190086A1 (ar) 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
UY38485A (es) 2018-11-27 2020-06-30 Novartis Ag Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación
US20230089867A1 (en) 2018-11-27 2023-03-23 Novartis Ag Cyclic pentamer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorder
WO2020110011A1 (en) 2018-11-27 2020-06-04 Novartis Ag Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorders
WO2023084449A1 (en) 2021-11-12 2023-05-19 Novartis Ag Diaminocyclopentylpyridine derivatives for the treatment of a disease or disorder
AR127698A1 (es) 2021-11-23 2024-02-21 Novartis Ag Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno
WO2024241229A1 (en) 2023-05-24 2024-11-28 Novartis Ag Naphthyridinone derivatives for the treatment of a disease or disorder

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588732A (en) * 1982-12-21 1986-05-13 Ciba-Geigy Corporation Certain imidazo(1,5-a)pyridine derivatives and their use as thromboxane synthetase inhibitors
US4617307A (en) * 1984-06-20 1986-10-14 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors
US6037349A (en) * 1991-03-27 2000-03-14 Merck Patent Gmbh Imidazopyridines

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1250844A (en) * 1981-06-22 1989-03-07 Neville Ford Substituted imidazo¬1,5-a|pyridines, process for their manufacture, pharmaceutical preparations containing these compounds and their therapeutic application
US5428160A (en) * 1982-12-21 1995-06-27 Ciba-Geigy Corporation Substituted imidazo[5-a]pyridine derviatives and other substituted bicyclic derivatives
US4470986A (en) * 1982-12-21 1984-09-11 Ciba-Geigy Corporation Certain imidazo (1,5-A) pyridine aliphatic carboxylic acid derivatives and their use as selective thromboxane inhibitors
US4889861A (en) * 1982-12-21 1989-12-26 Ciba-Geigy Corp. Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors
JPS615076A (ja) * 1984-06-19 1986-01-10 Toyama Chem Co Ltd 新規な１，４−ジヒドロピリジン誘導体およびその塩
GB8510541D0 (en) * 1985-04-25 1985-05-30 Wyeth John & Brother Ltd Heterocyclic compounds
US5529992A (en) * 1992-04-21 1996-06-25 Curators Of The University Of Missouri Method for inhibiting myocardial fibrosis by administering an aldosterone antagonist which suppresses aldoster one receptors
US6150347A (en) * 1992-04-21 2000-11-21 The Curators Of The University Of Missouri Use of aldosterone antagonists to inhibit myocardial fibrosis
JPH0971586A (ja) 1995-09-07 1997-03-18 Yamanouchi Pharmaceut Co Ltd 新規な二環性縮合イミダゾール誘導体
DE19701257A1 (de) * 1997-01-17 1998-07-23 Hannecke Wolf D Kunststoff Säulenpräsentationssystem in Modulbauweise zur Schaustellung von Waren oder Prospektmaterial und insbesondere von dünnen Gegenständen
US6887870B1 (en) 1999-10-12 2005-05-03 Bristol-Myers Squibb Company Heterocyclic sodium/proton exchange inhibitors and method

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588732A (en) * 1982-12-21 1986-05-13 Ciba-Geigy Corporation Certain imidazo(1,5-a)pyridine derivatives and their use as thromboxane synthetase inhibitors
US4617307A (en) * 1984-06-20 1986-10-14 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors
US6037349A (en) * 1991-03-27 2000-03-14 Merck Patent Gmbh Imidazopyridines

Also Published As

Publication number Publication date
PT1565463E (pt) 2008-09-10
WO2004046145A1 (en) 2004-06-03
US7223866B2 (en) 2007-05-29
HK1081540A1 (en) 2006-05-19
US7713991B2 (en) 2010-05-11
CN1711262A (zh) 2005-12-21
AU2003292039A1 (en) 2004-06-15
JP2006508970A (ja) 2006-03-16
DE60321593D1 (de) 2008-07-24
BR0316306A (pt) 2005-09-27
EP1565463A1 (en) 2005-08-24
EP1565463B1 (en) 2008-06-11
US20070197582A1 (en) 2007-08-23
US20060058342A1 (en) 2006-03-16
CA2505752A1 (en) 2004-06-03
ES2305520T3 (es) 2008-11-01
ATE398124T1 (de) 2008-07-15

Similar Documents

Publication Publication Date Title
CN100447142C (zh) 咪唑并[1,5a]吡啶衍生物及治疗醛固酮所介导疾病的方法
CN100404535C (zh) 用作治疗醛固酮介导的病症的药物的有机化合物
CN109071552B (zh) 细胞周期蛋白依赖性激酶4/6(cdk4/6)通过cdk4/6抑制剂与e3连接酶配体的缀合的降解及使用方法
TWI297269B (en) Compounds for the treatment of inflammatory disorders
US6380230B1 (en) Carboxamidothiazole derivatives, preparation, pharmaceutical compositions containing them
JP4700684B2 (ja) ２型糖尿病の処置に有用なグルコキナーゼアクティベーターとしてのスルホンアミド−チアゾロピリジン誘導体
BRPI0710110A2 (pt) compostos orgánicos
US8481731B2 (en) Compounds, pharmaceutical composition and methods relating thereto
EP1637521A1 (en) Novel tricyclic heterocycle compound
WO2005087767A1 (en) Hiv integrase inhibitors
AU2019353144B2 (en) Compounds and compositions for treating conditions associated with APJ receptor activity
CN107427506A (zh) 低分子量蛋白酪氨酸磷酸酶的抑制剂及其用途
CA2984618C (en) Histone deacetylase inhibitors and compositions and methods of use thereof
MXPA06011365A (es) Derivados de tiazolo-piridina, composiciones farmaceuticas que los contienen, y metodos para el tratamiento de condiciones mediadas por glucoquinasa.
CN118201917A (zh) 具有降解gspt1活性的化合物及其应用
CA3195014A1 (en) Preparation of benzimidazolone derivatives as novel diacylglyceride o-acyltransferase 2 inhibitors
HK1081540B (en) Imidazo[1,5a]pyridine derivatives and methods for treating aldosterone mediated diseases
HK1080290B (en) Organic compounds as agents for the treatment of aldosterone mediated conditions
NZ613087A (en) Histone deacetylase inhibitors and compositions and methods of use thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20081231

Termination date: 20111117